ArticleBMC infectious diseases2017
Cardiovascular disease risk among Chinese antiretroviral-naïve adults with advanced HIV disease.
Article in BMC infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- The prevalence of dyslipidemia and its correlation with anti-retroviral therapy among people living with HIV in China: a systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2025Pooled it
- Does infection with human immunodeficiency virus have any impact on the cardiovascular outcomes following percutaneous coronary intervention?: a systematic review and meta-analysis.BMC cardiovascular disorders · 2017Pooled it
- Early Warning and Behavioural Intervention on the Cardiovascular Disease Risk in People Living with HIV: A Multicentre Non-Randomized Controlled Trial.Infectious diseases and therapy · 2026Article
- Lipid profile dynamics and associated cardiovascular disease risk indices in Chinese people living with human immunodeficiency virus receiving antiretroviral therapy.BMC infectious diseases · 2026Article
- The predictive value of dyslipidemia for immune reconstitution outcome among HIV/AIDS patients after 24 months of viral suppression: a retrospective cohort study.BMC infectious diseases · 2026Article
- The Emerging Role of Interleukin-32 in HIV-Associated Cardiovascular Comorbidities: A Mini Review.International journal of general medicine · 2026Review
- Traditional Chinese medicine for HIV-related chronic comorbidities: evidence and potential therapeutic mechanisms.Frontiers in pharmacology · 2025Review
- Incidence and risk factors regarding atherosclerotic cardiovascular disease in middle-aged and elderly people with HIV treated in Chongqing, China.AIDS research and therapy · 2024Article
- Predictors of cardiovascular diseases among people living with HIV initiated on antiretroviral therapy in Khomas region, Namibia: A cross-sectional study.Journal of public health in Africa · 2022Article
- Article
- Multidisciplinary collaborative integrated management of increasingly prominent HIV complications in the post-cART era.HIV medicine · 2020Review
- Incidence of hypertension among persons living with HIV in China: a multicenter cohort study.BMC public health · 2020Article
- HIV and Aging in Mainland China: Implications for Control and Prevention Research.Current HIV/AIDS reports · 2019Review
- Cardiovascular disease incidence projections in the TREAT Asia HIV Observational Database (TAHOD).Antiviral therapy · 2019Article
- Improving access to antiretrovirals in China: economic analyses of dolutegravir in HIV-1 patients.Cost effectiveness and resource allocation : C/E · 2019Article
- Role of perceived heart risk factors by outpatient population in predicting cardiovascular risk.Journal of cardiovascular and thoracic research · 2019Article
- Continued Interest and Controversy: Vitamin D in HIV.Current HIV/AIDS reports · 2018Review
- Benefits and Risks of Statin Therapy in the HIV-Infected Population.Current infectious disease reports · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiovascular disease (CVD) is an important cause of mortality among HIV-infected patients, however little is known about the burden of CVD among this population in Asia. We sought to quantify prevalence of CVD risk factors, 10-year CVD risk, and patterns of CVD risk factor treatment in a group of individuals with HIV in China.
methodsWe retrospectively analyzed baseline data from treatment-naïve HIV-infected adults enrolled in two multicenter clinical trials in China. Data regarding CVD risk factors such as smoking, hypertension, diabetes, dyslipidemia and obesity were assessed. The Framingham Risk Score (FRS) and Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) risk scores were calculated to estimate 10-year CVD risk. The American College of Cardiology/American Heart Association Atherosclerotic Cardiovascular Disease (ASCVD) Risk Score was used to identify individuals meeting criteria for lipid-lowering therapy.
resultsIn total, 973 patients were included in the analysis. Mean age was 36.0 ± 10.2 years and 74.2% were men. The most common CVD risk factors were dyslipidemia (51.7%) and smoking (23.7%). Prevalence of hypertension, diabetes and obesity were 8.4%, 4.6% and 1.0%, respectively. Over 65% of patients had at least one CVD risk factor. The prevalence of 10-year risk of CVD ≥10% was 4.5% based upon FRS and was 3.3% based upon D:A:D risk score. Few patients with dyslipidemia, hypertension or diabetes were on treatment.
conclusionsCVD risk factors are common but under-treated among Chinese treatment-naïve individuals with HIV. Future interventions should focus on training HIV providers to appropriately recognize and manage CVD risk factors during routine clinical assessments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.